Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Extension Study of TS-152 (ozoralizumab) in Rheumatoid Arthritis
jRCT2080224848Phase 3Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Aug 2019
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of ozoralizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Taisho Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2080224848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224848.